Tregs present in tumor tissues have been found to express ICOS on their surface, and ICOS+ Tregs have been demonstrated to powerfully dampen T-cell responses indirectly through impairing antigen-presenting cells (APCs) with interleukin (IL)-10 (17). Here, ICOS is linked to neoplasm.